

Substance Intoxication or Withdrawal History and physical exam Urine toxicology

• Unknown substance(s)

- Lorazepam (PO/IM/IV), consider adding haloperidol if severely agitated or hallucinating
- PCP intoxication
- Lorazepam (PO/IM/IV/NGT)

• Alcohol/BZD withdrawal or stimulant intoxication

- Lorazepam (PO/IM/IV/NGT), add haloperidol if severely agitated or hallucinating
- Alcohol/BZD intoxication
 - Haloperidol (IM/PO) or chlorpromazine (PO/IM)

Opiate withdrawal

- Clonidine and/or opiate replacement (methadone, suboxone) per hosptial protocol
- Add symptomatic meds (ibuprofen, maalox, loperamide, ondansetron, dicyclomine) as needed
- Nicotine withdrawal (link to pathway)

Urine toxicology negative

Medication

Diphenhydramine

(antihistamine)

Risperidone

- Suspect synthetic cannabinoids or cathinones
- Lorazepam +/- haloperidol (PO/IM/IV) or chlorpromazine (PO/IM)

Delirium

Defined by: Acute onset/fluctuating course

plus

Inattention

plus Disorganized thinking or altered level of consciousness

- Address underlying medical etiology
- Assess pain
- · Avoid benzodiazepines and anticholinergics which may worsen delirium

Medications for patients still severely agitated

- PO: quetiapine or risperidone or clonidine
- IM: olanzapine or chlorpromazine
- IV: haloperidol

Dose / Re-administration

PO/IV/IM: 12.5 - 50mg

(1 mg/kg/dose)

• Lorazepam (PO/IM/IV/NGT) if there are seizure concerns or catatonia

Peak Effect

PO: 2 hours

PO: 1 hour

Developmental Delay or

• Note: Pts with ASD/DD are at higher risk for delirium and medical or psych symptoms

- Assess pain, hunger, other
- · Consider using visual
- Utilize sensory tools
- Ask what usually soothes child
- Ask about prior medication responses (positive or negative), especially to benzodiazepines and diphenhydramine

Medications for patients still severely agitated:

- Consider extra dose of pt's regular standing medication
- Avoid benzodiazepines due to risk for disinhibition
- PO route preferred
- diphenhydramine (PO/IM) or antipsychotic (risperidone PO, chlorpromazine PO/IM or olanzapine PO/IM/ODT)

Max Daily Dose (MDD)

Child: 50 - 100 mg Adolescent:

100 - 200 mg

Psychiatric Diagnosis

- · History to clarify diagnosis and reason for agitation
- Use behavioral deescalation
- strategies

Lorazepam (PO/IM/IV/NGT)

• Anxiety, trauma, or PTSD

Lorazepam (PO/IM/IV) or

• Clonidine (PO) (if <12 yo or

concern for disinhibition)

diphenhydramine (PO/IM) or

Risperidone (PO) "if concern

Oppositional Defiant Disorder

Chlorpromazine or lorazepam

(PO/IM) or olanzapine (PO/IM)

PO: Risperidone or quetiapine

haloperdiol +/- lorazepam

(add diphenhydramine for

extrapyramidal symptoms) or

If on standing antipsychotic,

Agitated catatonia

Clonidine (PO) or

for hypotension"

or Conduct Disorder

or risperidone (PO)

(extremely rare under 12)

· IM: Chlorpromazine or

· Mania or psychosis

olanzapine

give extra dose

ADHD

Agitation

Unknown Etiology for

- · History and physical exam
- Use behavioral deescalation strategies
- Continually reevaluate for other cause of agitation

• Mild agitation (e.g., verbal aggression)

- Utilize behavioral and environmental strategies to deescalate
- Moderate agitation (e.g., aggression against objects or property destruction)
- Diphenhydramine (PO/IM) or lorazepam (PO/IM) or olanzapine (PO/IM)

• Severe agitation (e.g., * aggression to self or other)

· Chlorpromazine (PO/IM) or haloperidol + lorazepam (PO/IM) or olanzapine (PO/IM)

*Do not give olanzapine and benzodiazepines within one hour of each other (due to risk of respiratory suppression)

Autism

- Attempt behavioral interventions
- physical needs
- communication tools

- · Clonidine (PO) or

Redosing Onset Notes/monitoring Frequency Avoid in delirium. Can cause disinhibition or PO: 15 - 60 min Q 4 - 6 hours delirium in younger or DD youth. May cause QT IV/IM: 15 min

prolongation.

Can cause disinhibition or delirium in younger or Child: 4 mg DD youth. Can be given with haloperidol, PO 20 - 30 min PO/IV/IM/NGT: 0.5 mg - 2 mg IV: 10 minutes Adolescent: 6 - 8 mg Lorazepam IV 2 - 5 min Q 1 - 2 hours chlorpromazine or risperidone. Do not give with (benzodiazepine) (0.05 - 0.1 mg/kg/dose) PO/IM: 1 - 2 hours Depending on weight/prior IM 15 - 30 min olanzapine (especially IM due to risk of respiratory medication exposure suppression). 27 - 40.5 kg: 0.2 mg/day 40.5 Monitor for hypotension and bradycardia. Avoid Clonidine PO: 0.05 mg - 0.1 mg PO: 30-60 minutes 45 kg: 0.3 mg/day No reliable data Q8 hours giving with BZD or atypical antipsychotic due to (alpha-2 agonist) >45 kg: 0.4 mg/day hypotension risk. PO: 12.5 - 50 mg Child <5 years: 40mg/day Monitor for hypotension. Monitor for QT Chlorpromazine PO: 30-60 minutes (0.55 mg/kg/dose) Q 4 hours 30 - 60 min (antipsychotic) IM: 15 minutes Child >5 years: 75mg/day prolongation. IM: 0.28mg/kg (max 25mg) Monitor for hypotension. Consider EKG or cardiac monitoring for QT prolongation, especially for IV 15-40 kg: 6mg administration. Note: Risk of extrapyramidal side effects (EPS) with Haloperidol PO/IM: 0.5 mg - 5 mg PO: 2 hours >40 kg: 15 mg 30 - 60 min Q 4 hours IM: 20 minutes Depending on prior MDD >3mg/day, with IV dosing having very high (antipsychotic) (0.55 mg/kg/dose) antipsychotic exposure EPS risk. Consider pairing with diphenhydramine to reduce risk of EPS (if not concerned for QT prolongation) 10 - 20 mg PO: 5 hours (range Olanzapine Do not give with or within 1 hour of any BZD given PO/ODT or IM: 2.5 - 10 mg Depending on antipsychotic Q 2 hours 15 min 1-8 hours) (atypical antipsychotic) risk for respiratory suppression.

exposure IM: 15-45 minutes Child: 1 - 2 mg

(atypical antipsychotic) (0.005-0.01mg/kg/dose) Depending on antipsychotic hours higher doses. exposure >10 years: 600 mg Depending Quetiapine More sedating at lower doses. Monitor for PO: 25 - 50 mg PO: 30 minutes-2 on prior antipsychotic No reliable data Q 12 hours (1-1.5 mg/kg/dose or divided) (atypical antipsychotic) hours hypotension. exposure

Adolescent: 2 - 3 mg

Initially developed by Gerson et al., (2023) and has been reconceptualized by Children's Mercy Kansas City. Gerson, R., Malas, N., Feuer, V., Silver, G. H., Prasad, R., & Mroczkowski, M. M. (2023). Best Practices for Evaluation and Treatment of Agitated Children and Adolescents (BETA) in the Emergency Department: Consensus Statement of the American Association for Emergency Psychiatry. Focus, 21(1), 80-88.

Q 0.5 - 2

60 - 70 min

PO/ODT: 0.25 - 1mg

Can cause akathisia (restlessness/agitation) in